Tandem Diabetes Care
TNDM
337 hedge funds and large institutions have $7.32B invested in Tandem Diabetes Care in 2021 Q3 according to their latest regulatory filings, with 79 funds opening new positions, 106 increasing their positions, 106 reducing their positions, and 39 closing their positions.
103% more first-time investments, than exits
New positions opened: 79 | Existing positions closed: 39
80% more funds holding in top 10
Funds holding in top 10: 5 → 9 (+4)
27% more capital invested
Capital invested by funds: $5.75B → $7.32B (+$1.57B)
11% more funds holding
Funds holding: 303 → 337 (+34)
3% more ownership
Funds ownership: 94.25% → 97.25% (+3%)
0% more repeat investments, than reductions
Existing positions increased: 106 | Existing positions reduced: 106
4% less call options, than puts
Call options by funds: $76.9M | Put options by funds: $80.4M
Top Buyers
| 1 |
BlackRock
New York
|
+$252M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$49.2M |
| 3 |
State Street
Boston,
Massachusetts
|
+$46.5M |
| 4 |
Goldman Sachs
New York
|
+$40.5M |
| 5 |
Bank of New York Mellon
New York
|
+$37.2M |
Top Sellers
| 1 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$71M |
| 2 |
CCM
Consonance Capital Management
New York
|
-$54.2M |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$39.1M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$35.4M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$19.2M |
TNDM Hedge Fund Activity: Q3 2021 in Review
337 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Tandem Diabetes Care (TNDM) for Q3 2021, worth a combined $7.32B — up 27% from $5.75B a quarter earlier.
Buyers outnumbered sellers: 79 funds opened new TNDM positions and 39 closed out — a net gain of 40 holders — while 106 added to existing stakes and 106 trimmed.
The largest buyer was BlackRock, adding an estimated $252M. The largest seller was Credit Suisse, cutting an estimated $71M.
- 337 institutional investors held Tandem Diabetes Care (TNDM) as of Q3 2021, up from 303 in Q2 2021.
- Funds reported $7.32B of Tandem Diabetes Care stock for Q3 2021, up 27% quarter-over-quarter.
- 79 funds opened new Tandem Diabetes Care positions in Q3 2021 and 39 closed out, a net change of +40 holders.
- The largest Tandem Diabetes Care buyer in Q3 2021 was BlackRock, an estimated $252M added.
- The largest Tandem Diabetes Care seller in Q3 2021 was Credit Suisse, an estimated $71M sold.
Based on aggregated 13F filings for Q3 2021.